1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : virtual event on key ophthalmology data presented at the Angiogenesis 2022 Meeting

01/17/2022 | 08:05am EDT
Investor Update Roche's virtual event on key ophthalmology data presented at the Angiogenesis 2022 Meeting

We are pleased to invite investors and analysts to participate in our virtual event on Monday,
14 February 2022,
highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2022 Meeting, from 11th to 12th February.

16:30 - 17:45 CET / 15:30 - 16:45 GMT
10:30 - 11:45 am EST / 7:30 - 8:45 am PST

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CET on the day of the event.
> click here

Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Sabine Borngräber
Investor Relations Officer

Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com


Roche Holding AG published this content on 17 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 January 2022 13:04:16 UTC.

ę Publicnow 2022
All news about ROCHE HOLDING AG
09:29aAlphaValue/Baader Europe Lifts Price Target on Roche, Maintains Add Recommendation
05/16TRANSCRIPT : Roche Holding AG - Special Call
05/13PUMP / DUMP #31 : The week's gainers and losers
05/13ROCHE HOLDINGS AG : Reduced to Neutral by Jefferies
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
05/12ROCHE HOLDINGS AG : Gets a Neutral rating from Morgan Stanley
05/12ROCHE HOLDINGS AG : Deutsche Bank lowers his opinion and switches to Neutral
05/12Roche Teams Up With Global Fund To Boost Diagnostic Systems In Low, Middle-income Natio..
05/12Roche enters partnership with the Global Fund to support low- and middle-income countri..
05/11New class of cancer drugs down, not out, after Roche trial setback - analysts
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Sales 2022 64 123 M 64 595 M 64 595 M
Net income 2022 14 877 M 14 986 M 14 986 M
Net Debt 2022 10 808 M 10 887 M 10 887 M
P/E ratio 2022 17,3x
Yield 2022 3,01%
Capitalization 262 B 264 B 264 B
EV / Sales 2022 4,25x
EV / Sales 2023 4,08x
Nbr of Employees 100 920
Free-Float 82,4%
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 322,35 CHF
Average target price 394,40 CHF
Spread / Average Target 22,4%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-14.96%260 807
JOHNSON & JOHNSON4.10%468 600
PFIZER, INC.-14.19%284 304
ABBVIE INC.14.82%274 733
MERCK & CO., INC.20.46%233 459